Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Holdings Trimmed by Yelin Lapidot Holdings Management Ltd.

Yelin Lapidot Holdings Management Ltd. cut its holdings in Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) by 5.3% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 35,887 shares of the company’s stock after selling 2,018 shares during the quarter. Yelin Lapidot Holdings Management Ltd.’s holdings in Harmony Biosciences were worth $1,235,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Pacer Advisors Inc. raised its holdings in shares of Harmony Biosciences by 18.2% in the 4th quarter. Pacer Advisors Inc. now owns 2,279,918 shares of the company’s stock worth $78,452,000 after purchasing an additional 351,582 shares in the last quarter. Massachusetts Financial Services Co. MA increased its holdings in shares of Harmony Biosciences by 27.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 660,391 shares of the company’s stock valued at $26,416,000 after buying an additional 140,690 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in shares of Harmony Biosciences by 13.8% in the fourth quarter. Bank of New York Mellon Corp now owns 265,639 shares of the company’s stock valued at $9,141,000 after buying an additional 32,272 shares in the last quarter. JPMorgan Chase & Co. boosted its stake in shares of Harmony Biosciences by 68.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 230,428 shares of the company’s stock worth $9,217,000 after acquiring an additional 93,622 shares in the last quarter. Finally, Principal Financial Group Inc. grew its holdings in shares of Harmony Biosciences by 28.4% in the 4th quarter. Principal Financial Group Inc. now owns 208,663 shares of the company’s stock worth $7,180,000 after acquiring an additional 46,194 shares during the last quarter. 86.23% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the company. Mizuho decreased their price target on Harmony Biosciences from $52.00 to $42.00 and set an “outperform” rating for the company in a research report on Thursday, February 20th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Harmony Biosciences in a report on Tuesday, February 11th. They issued a “buy” rating and a $55.00 target price for the company. HC Wainwright cut their price target on shares of Harmony Biosciences from $75.00 to $70.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $50.00 price objective on shares of Harmony Biosciences in a research note on Tuesday. Nine analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and an average target price of $53.11.

Insider Activity at Harmony Biosciences

In other news, CEO Jeffrey M. Dayno sold 19,293 shares of the stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total transaction of $774,228.09. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Sandip Kapadia sold 25,000 shares of the firm’s stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $40.18, for a total transaction of $1,004,500.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 72,452 shares of company stock valued at $2,831,679. 30.80% of the stock is currently owned by corporate insiders.

Harmony Biosciences Trading Down 2.2 %

NASDAQ HRMY opened at $32.75 on Friday. The company has a market capitalization of $1.87 billion, a PE ratio of 15.52, a price-to-earnings-growth ratio of 0.47 and a beta of 0.80. Harmony Biosciences Holdings, Inc. has a 1-year low of $28.14 and a 1-year high of $41.61. The company has a current ratio of 3.24, a quick ratio of 3.20 and a debt-to-equity ratio of 0.28. The firm’s fifty day simple moving average is $36.66 and its 200-day simple moving average is $35.81.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings results on Tuesday, February 25th. The company reported $0.85 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.11. The company had revenue of $201.30 million during the quarter, compared to the consensus estimate of $201.25 million. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The business’s quarterly revenue was up 19.5% on a year-over-year basis. During the same period last year, the business earned $0.45 EPS. As a group, sell-side analysts anticipate that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current fiscal year.

Harmony Biosciences Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.